Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues

Cancer Investigation

Volumn 18, Issue 6, 2000, Pages 516-520

  Nagakawa, Takukazu ^c   Kayahara, Masato ^a   Ohta, Tetsuo ^a   Kitagawa, Hirohisa ^a   Mikami, Kiyohiro ^b   Kurata, Takashi ^b   Otsuji, Shun ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c Otsuka Pharmaceutical Co Ltd ^*

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PANCREAS CANCER; PRIORITY JOURNAL;

EID: 0033930019     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009012190     Document Type: Article

References (15)

1. Fujii S, Kitano S, Ikenaka K: Effect of co-administration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-rluorouracil and the level of 5-fluorouracil in rodents. Gann 70:209-214, 1979.
2. Fujii S, Fukushima M, Shimamoto Y, et al: Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn J Cancer Res 80: 173-181, 1989.
3. Tatsumi K, Yamauchi T, Kiyono K, et al: 3-Cyano-2,6-dihydropyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. J Biochem 114:912-918, 1993.
4. Fujita F, Fujita M, Inaba H, et al: Antitumor activity of BOF-A2, 4 a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration. Jpn J Cancer Chemother 20:223-228, 1993.
5. Shirasaka T, Fujita F, Fujita M, et al: Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice. Jpn J Cancer Chemother 17:1871-1876, 1990.
6. Nakajima Y, Yoshimura A, Nakano H, et al: Multicenter late phase II study of BOF-A2 in pancreatic cancer. Can J Infect Dis 6(Suppl C):438C, 1995.
7. Nakai Y, Furuse K, Ohta M. et al: Efficacy of a new 5-fluorouracil derivatives, BOF-A2, in advanced non small cell lung cancer. Acta Oncol 33:523-526, 1994.
8. Naquib FNM, et Kouni MH, Cha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45:5405-5412, 1985.
9. Maehara Y, Nagayama S, Okazaki H, et al: Metabolism of 5-fluorouracil in various human normal and tumor tissues. Gann 72: 824-827, 1981.
10. Dah HL, Townsend L, Luna MA, et al: Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 6:781-784, 1986.
11. Fleming RA, Milano G, Thyss A, et al: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902, 1992.
12. Matsui Y, Izumi T, Niitani H: Clinical study of 5-FU concentration in the tissue of patients with primary lung cancer treated by oral BOF-A2. J Jpn Soc Cancer Ther 27:565, 1992.
13. Okayasu T, Sugiyama K, Miyauchi S: Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues. Jpn Cancer Res 85:101-105, 1994.
14. Beck A, Etienne MC, Cheradame S, et al: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30A:1517-1522, 1994.
15. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13:1663-1670, 1995.